Aesthetics Company Sinclair Pharma (Ellansé, Silhouette, Perfectha, Lanluma) is entering the energy-based devices market with the acquisition of Cocoon Medical.
Spanish-founded Cocoon Medical has an extensive portfolio of non-invasive lasers and cryoadipolisis (freeze-induced fat cell apoptosis) devices such as the Cooltech Define, Primelase and Elysion for clinics and medi-spas.
The manufacturer has a direct presence in Europe, Latin America, Hong Kong and the US and manages a network of over 60 distributors in other countries.
Sinclair’s newly-created energy-based devices division will be overseen by current Cocoon chief executive Miguel Pardos and headquartered in Barcelona, Spain.
Chris Spooner, chief executive of Sinclair commented, “The acquisition rationale was compelling. Cocoon came to our attention as a conservatively managed company which since inception, has steadily grown its business, presence and reputation by investing primarily in developing its in-house R&D and manufacturing standards.
“As a consequence, Cocoon’s products combine outstanding technology, build quality and user flexibility with competitive pricing to generate an industry-leading value proposition. Moreover, the company has a rich product development pipeline to sustain its technological edge for several years.”
